<DOC>
	<DOC>NCT02029209</DOC>
	<brief_summary>1. To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the phase II study of anlotinib in patients with advanced non-small cell lung cancer. 2. To clarify the meaning of peripheral markers and blood perfusion parameters in vivo tumor in predicting the effect of anti-angiogenic therapy.</brief_summary>
	<brief_title>To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>1. Pathology diagnosed with advanced NSCLC with measurable lesions; 2. Have failed for 2 lines of chemotherapy; 3.1870 years,ECOG PS:02,life expectancy of more than 3 months; 4.Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks; 5.Main organs function is normal; 6.Women of childbearing age should take contraceptive measures during the study and within 6 months after end. 1. SCLC(including mixed with NSCLC); 2. The central cavity of Squamous cell carcinoma and hemoptysis with NSCLC; 3. Patients failed to use the antitumor angiogenesis therapy; 4. Patients have many influence factors toward oral medications ; 5. Brain metastases patients accompanied by symptoms or symptom control for less than two months; 6. Patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG&gt;10mmol/L);urine protein≥++,etc. 7. Patients failed to heal wounds or fractures for Longterm; 8. 4 weeks before enrollment, patients appeared NCI CTC AE grading &gt;1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade&gt; 2 had other parts of the bleeding; patients have a tendency to bleed (e.g active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as Warfarin, heparin or its analogues; 9. Patients occurred venous thromboembolic events within 6 months; 10. Patients who have HIVpositive or organ transplantation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>